Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination

Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination

Background: Immune protection following either vaccination or infection with SARS-CoV-2 decreases over time. Objective: We aim to describe clinical and sociodemographic characteristics associated with COVID-19 infection at least 14 days after booster vaccination in the Israeli population. Methods: W...

Full description

Bibliographic Details
Main Authors: Ariel Israel, Eugene Merzon, Yotam Shenhar, Ilan Green, Avivit Golan-Cohen, Alejandro A. Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Vaccines
Subjects:
BNT162b2
mRNA
vaccine
SARS-CoV-2
infection
convalescents
Online Access:https://www.mdpi.com/2076-393X/10/5/636

Similar Items

Similar Items